Please assess the completion status of the following clinical trial:

Trial Title: ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Written informed consent prior to admission to this study~* 2. Aged 18≥over~* 3. Histologically confirmed ER+ve metastatic breast cancer according to local criteria~* 4. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2~* 5. Have progressed after at least one hormonal therapy regime and at least one chemotherapy regime for advanced disease~* 6. Patients must have had prior treatment with an anthracycline and a taxane (either sequential or in combination) unless patients were not suitable for these treatments. This treatment can be in the adjuvant setting~* 7. Measurable sites of locally advanced and/or metastatic disease that can be accurately assessed by CT/MRI scan at baseline (RECIST v1.1)¹~* 8. Life expectancy of ≥6 months~* 9. Adequate organ function, as defined by:~  * Haemoglobin (Hb) ≥ 9 g/dL~ * Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L~ * Platelet count (Plts) ≥ 100 x 109/L~ * White Blood Cell (WBC) ≥ 3.0 x 109/L~ * Serum albumin ≤ 1.5 Upper Limit of Normal (ULN)~ * Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 3 x ULN if no demonstrable liver metastases or ≤ 5 x ULN in the presence of liver metastases.~ * Alkaline Phosphatase Level (ALP) ≤ 5 x ULN~ * Total bilirubin ≤ 1.5 x ULN if no demonstrable liver metastases or ≤ 3 x ULN in the presence of liver metastases~ * Creatinine ≤ 1.5 x ULN or creatinine clearance \>50ml/min~* 10. Postmenopausal as defined by age \>50, no menstruation for \>2 years, previous oophorectomy or lab results confirming this status~* 11. Premenopausal if has been subject to ovarian ablation/ suppression at least 3 weeks prior to commencing AI therapy~  * RECIST v1.1 updated and now considers bone metastasis with an identifiable soft tissue mass to be measurable disease. Therefore, patients with bone metastasis are eligible, provided they have evaluable disease.~Exclusion Criteria:~* 1.Triple negative or Human Epidermal Growth Factor Receptor 2 (HER2) positive cancer~* 2. Hypersensitivity to the active substance or to any of its excipients~* 3. History of another primary malignancy within 5 years prior to starting study treatment, except adequately treated basal or squamous cell carcinoma of the skin, carcinoma in site and the disease under study~* 4. Evidence of uncontrolled active infection~* 5. Severe hepatic impairment (Child-Pugh C)~* 6. Evidence of significant medical condition or laboratory finding which, in the opinion of the Investigator, makes it undesirable for the patient to participate in the trial~* 7. Concurrent therapy with any other investigational agent or everolimus~* 8. Concomitant use within 14 days prior to commencement of study treatment of any investigational agent~* 9. Uncontrolled abnormalities of serum potassium, sodium, calcium (corrected) phosphate or magnesium levels~* 10. Pregnant or lactating women. Effective non-hormonal contraception is mandatory for all patients of reproductive potential~* 11. Evidence of ovarian activity~* 12. Prior eribulin therapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm study (Type: EXPERIMENTAL): 3 x 3 weekly cycles at the recommended dose of eribulin as the ready to use solution, 1.23 mg/m2, administered intravenously over 2-5 minutes on days 1 and 8 of every 21 day cycle. This will then be followed by 9 weeks of AI treatment, to be followed again by 3 x 3 weekly cycles of eribulin and 9 weeks AI treatment. Patients will remain on treatment for up to 9 months, or until disease progression or unacceptable toxicities, whichever is sooner.

Based on this trial design, predict the completion outcome and termination type (if applicable).